Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/127053
Full metadata record
DC FieldValueLanguage
dc.creatorBettencourt-Silva, R-
dc.creatorQueirós, J-
dc.creatorPereira, J-
dc.creatorCarvalho, D-
dc.date.accessioned2020-05-13T10:50:35Z-
dc.date.available2020-05-13T10:50:35Z-
dc.date.issued2018-
dc.identifier.issn1752-1947-
dc.identifier.urihttps://hdl.handle.net/10216/127053-
dc.description.abstractBackground: Giant prolactinomas are very rare pituitary tumors that may exhibit an aggressive behavior and present with a life-threatening condition. Case presentation: A 25-year-old white woman was admitted to our hospital with a headache, psychomotor retardation, reduced vision, and loss of autonomy in daily activities. Her past medical history was significant for having oligomenorrhea and a depressive syndrome since her mother's death. She also had a breast cancer gene 1 (BRCA1) mutation and a family history of breast cancer. She had marked hyperprolactinemia (7615 ng/dL), central hypocortisolism, growth hormone deficiency, and a giant pituitary tumor (52 × 30 × 33 mm) which was shown in magnetic resonance imaging with obstructive hydrocephalus, requiring emergency surgery. Treatment with cabergoline led to a 99.8% reduction in serum prolactin levels and significant tumor shrinkage. Her depressive symptoms progressively improved and psychiatric drugs were withdrawn after 3 months of cabergoline treatment. Currently, she is being followed in Endocrinology, Neurosurgery, and Neurophthalmology out-patient clinics and in a breast cancer unit. Careful monitoring, support, and follow-up will be essential throughout this patient's life. Conclusions: This case is a rare presentation of a giant prolactinoma in a young woman, who presented a life-threatening event. She also had an unexpected association between diseases or symptoms that may have contributed to the delay in diagnosis. Given the concomitant presence of a giant prolactinoma, a BRCA1 mutation, and depressive symptoms, a possible association was hypothesized. The breast cancer risk in a BRCA1 mutation carrier and the possible interference of hyperprolactinemia and life events were also discussed. However this hypothesis requires further investigation.-
dc.language.isoeng-
dc.publisherBMC-
dc.relation.ispartofJournal of Medical Case Reports, vol.12(1):360-
dc.rightsopenAccess-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subject.meshAdult-
dc.subject.meshAntidepressive Agents / therapeutic use-
dc.subject.meshBRCA1 Protein / genetics-
dc.subject.meshCabergoline / therapeutic use-
dc.subject.meshDepressive Disorder / complications-
dc.subject.meshDepressive Disorder / drug therapy-
dc.subject.meshDopamine Agonists / therapeutic use-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMagnetic Resonance Imaging / methods-
dc.subject.meshMutation / genetics-
dc.subject.meshPituitary Neoplasms / complications-
dc.subject.meshPituitary Neoplasms / diagnostic imaging-
dc.subject.meshPituitary Neoplasms / therapy-
dc.subject.meshProlactinoma / complications-
dc.subject.meshProlactinoma / diagnostic imaging-
dc.subject.meshProlactinoma / therapy-
dc.titleGiant prolactinoma, germline BRCA1 mutation, and depression: A case report 11 Medical and Health Sciences 1103 Clinical Sciences 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis-
dc.typeArtigo em Revista Científica Internacional-
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde-
dc.identifier.doi10.1186/s13256-018-1890-x-
dc.relation.publisherversionhttps://jmedicalcasereports.biomedcentral.com/articles/10.1186/s13256-018-1890-x-
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.1186-s13256-018-1890-x.pdf3.84 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons